Last reviewed · How we verify

regional anesthesia and PAI

Washington University School of Medicine · FDA-approved active Small molecule

Regional anesthesia combined with plasminogen activator inhibitor (PAI) modulation reduces pain and inflammation at the injection site while potentially modulating fibrinolytic activity.

Regional anesthesia combined with plasminogen activator inhibitor (PAI) modulation reduces pain and inflammation at the injection site while potentially modulating fibrinolytic activity. Used for Postoperative pain management, Regional anesthesia adjunct.

At a glance

Generic nameregional anesthesia and PAI
Also known asadductor canal block, periarticular injection
SponsorWashington University School of Medicine
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

This appears to be a combination approach using regional anesthetic techniques (local nerve blocks or infiltration) paired with PAI (plasminogen activator inhibitor) to manage postoperative pain and potentially reduce bleeding or thrombotic complications. The regional anesthetic component blocks nerve conduction locally, while PAI modulation may influence fibrinolysis and hemostasis in the surgical field.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: